Dynavax Technologies Corp (NAS:DVAX)
$ 13 -0.03 (-0.23%) Market Cap: 1.71 Bil Enterprise Value: 1.17 Bil PE Ratio: 100.23 PB Ratio: 2.51 GF Score: 70/100

Dynavax Technologies Corp at JMP Securities Life Sciences Conference Transcript

May 15, 2023 / 05:00PM GMT
Release Date Price: $11.46 (+4.85%)
Roy Buchanan
JMP Securities - Analyst

All right. Well, thank you again for joining us at JMP Securities Life Science Conference. My name is Roy Buchanan. I'm one of the biotech equity analysts researcher. We're happy to have the next company with us, Dynavax Technologies. And here on stage, we have Ryan Spencer, the CEO; and in the audience is Kelly MacDonald, CFO. We have Nicole Spencer and Paul Cox on the Investor Relations team.

So thank you for joining us, Ryan, to give us the download on Dynavax.

Questions & Answers

Roy Buchanan
JMP Securities - Analyst

Pretty exciting year coming up, you guys, exciting financial results pretty much every quarter now, but maybe give us a 30-second intro to what Dynavax is and what you're doing.

Ryan Spencer
Dynavax Technologies Corporation - CEO

Well, first of all, thank you for having us, Roy. We really appreciate it. The short intro is we've been organizing mostly around our adult hepatitis B vaccine, HEPLISAV-B, as you noted, has been making great

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot